Compare ADMA Biologics Inc (ADMA) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs DexCom, Inc. — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while DexCom, Inc. trades at $89.2 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 15.2× ADMA Biologics Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DXCM | |
|---|---|---|
Market Cap | $2.22B | $33.79B |
Sector | Health | Health |
52-Week High | $20.38 | $89.53 |
52-Week Low | $7.60 | $54.84 |
Enterprise Value | $2.29B | $33.24B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
